AI Stock Memo: GILD - Gilead Sciences - RankAlpha

GILD

Rating buyAI Memo

Gilead Sciences

As of 2026-02-11/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-02-11 • Model: RankAlpha Sentiment AI

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

buy

Confidence

medium

Horizon

—

Key catalyst

Next quarterly results (estimated) • 2026-05-12

Expected move: +8%

Biggest risk

Bear case: HIV pricing pressure, competitive share losses, or clinical/regulatory setbacks compress multiples and push the stock toward the low analyst target.

Invalidation

Break below $103 or thesis failure.

What would change my mind?

Bull case: Durable HIV revenue growth, stronger-than-expected adoption of long‑acting therapies (e.g., Cabenuva), and positive late‑stage readouts drive margin expansion and multiple re-rating toward the top analyst target.

Research note

Recommendation

buy

Confidence

medium

As of

2026-02-11

Base target

$147

p=60%

Bull target

$170

p=20%

Bear target

$103

p=20%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

HIV franchise sustained growth (Biktarvy/Cabenuva)
Bull case: Durable HIV revenue growth, stronger-than-expected adoption of long‑acting therapies (e.g., Cabenuva), and positive late‑stage readouts drive margin expansion and multiple re-rating toward the top analyst target.
ANCHOR: {"price": 144.1, "timestamp_utc": "2026-02-11T13:11:54+00:00", "source": "broker_last"} ANALYST_TARGETS_REVIEWED: true Scenario targets reference the authoritative anchor above; base_target (146.835) aligns with the analyst median, bull_target (170.0) aligns with the analyst high, and bear_target (103.0) aligns with the analyst low, reflecting the observed analyst distribution and the consensus spread [#SERP-2], [#SERP-6].

BearKey bullets

HIV pricing pressure and competitive share loss
Patent/litigation loss or earlier-than-expected generic entry
Pipeline clinical failure or adverse regulatory decision

WatchKey bullets

Next quarterly results (estimated)

Summary

High-level snapshot

Recommendation

buy

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $147 (p=60%)

Bull/Bear spread: +25% / -24%

Vs latest close: Bull +25% · Base +8% · Bear -24%

Scenario probabilities

Bull Target: $170 (p=20%)Base Target: $147 (p=60%)Bear Target: $103 (p=20%)

Commentary

Market tone is mixed: consensus median sits near our base case while select broker upgrades have pushed upside expectations toward the high‑$160s–$170s, signaling selective conviction on HIV strength [#SERP-4][#SERP-6]. The wide low–high spread reflects event-driven risk; near-term earnings and readouts will likely determine short-term direction.

As of 2026-02-11 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Bear case: HIV pricing pressure, competitive share losses, or clinical/regulatory setbacks compress multiples and push the stock toward the low analyst target.

Drivers

Scannable catalysts and supporting factors

HIV franchise sustained growth (Biktarvy/Cabenuva)

Human Analyst Targets

External snippets for comparison only; verify at source.

Unverified externalLast fetched 2026-02-11Source quality: external scrape

External snippets are unverified; treat as directional signals only. Always confirm with the original provider.

Inline RA est

Provider

serper

Median (USD)

$146.83

Range (USD)

$103.00 - $170.00

Count

Query: Gilead Sciences Inc Common (GILD) analyst consensus price target high low average

Gilead Sciences, Inc. (GILD) Stock Price, News, Quote & History
Search result #1
Find the latest Gilead Sciences, Inc. (GILD) stock quote, history, news and other vital information to help you with your stock trading and investing.
Open source
Gilead Sciences (GILD) Stock Forecast, Price Targets and Analysts ...
Search result #2
The average price target is $141.63 with a high forecast of $156.00 and a low forecast of $103.00. The average price target represents a -7.13% change from the ...
Extracted: $141.63, $156.00, $103.00Open source
Gilead Sciences, Inc.: Target Price Consensus and Analysts ...
Search result #3
Spread / Average Target. -5.43%. High Price Target. 159.00USD. Spread / Highest target. +7.99%. Low Price Target. 103.00USD. Spread / Lowest Target. -30.04% ...
Extracted: $159.00, $103.00Open source
Gilead Sciences Inc. Analyst Estimates - GILD - MarketWatch
Search result #4
Stock Price Targets. High, $159.00. Median, $142.50. Low, $103.00. Average, $139.83. Current Price, $152.50. Yearly Numbers. Estimates. GILD will report 2025 ...
Extracted: $159.00, $142.50, $103.00, $139.83, $152.50Open source
GILD Stock Price Quote & News - Gilead Sciences - Robinhood
Search result #5
In a report released yesterday, Geoff Meacham from Citi maintained a Buy rating on Gilead Sciences, with a price target of $156.00. Valentine's Day Sale - 70% O ...
Extracted: $156.00Open source
Needham raises Gilead Sciences stock price target to $170 on ...
Search result #6
Needham raises Gilead Sciences stock price target to $170 on strong HIV sales.
Extracted: $170.00Open source11 minutes ago

Scenarios

Bull Target (Scenario probability)

$170 / p=20% prob

Base Target (Scenario probability)

$147 / p=60% prob

Bear Target (Scenario probability)

$103 / p=20% prob

Price $136 as of 2026-05-28

Nearest Scenario: Base (∆ 8%)

Targets vs latest close: Bull +25% · Base +8% · Bear -24%

Sentiment & Exposure

Sentiment unavailable: insufficient coverage

Events

Other notable items detected

EVENT2026-05-12
Next quarterly results (estimated)
Estimated quarterly results event; date conservatively assumed as 2026-05-12 (no confirmed date disclosed here). Results can re-price shares if HIV/oncology revenues diverge from expectations [#SERP-4].
Prob 65.00% • Move 5.00% • Priced-in 40.00%

Short-term Catalysts

Next few weeks

No short-term catalysts

Long-term Catalysts

Months to a year

HIV franchise sustained growth (Biktarvy/Cabenuva)
2027-02-11
Continued HIV product momentum could drive significant top-line upside over the next 12 months; recent analyst notes cite strong HIV sales as a reason for higher targets [#SERP-6].
Prob 75% • Move 25% • Priced-in 60%

Risks

HIV pricing pressure and competitive share loss
Patent/litigation loss or earlier-than-expected generic entry
Pipeline clinical failure or adverse regulatory decision

Peers

Symbol	Summary
ABBV	Large specialty biopharma with comparable commercial scale and durable franchise management; useful benchmark for margins, cash return, and franchise longevity.
MRK	Global diversified pharma with strong infectious disease and oncology franchises; relevant comparator for R&D productivity and regulatory execution.
BMY	Diversified pharmaceutical peer with sizable oncology and antiviral assets; comparable for late‑stage commercialization and pipeline execution.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment AI
Human targets: serper
Targets query: Gilead Sciences Inc Common (GILD) analyst consensus price target high low average
Analysis date: 2026-02-11